Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Elena Ratner, MD, MBA

Professor of Obstetrics, Gynecology & Reproductive Sciences; Co-Chief, Section of Gynecologic Oncology

Contact Information

Elena Ratner, MD, MBA

Office Location

Mailing Address

  • Obstetrics, Gynecology & Reproductive Sciences

    PO Box 208063

    New Haven, CT 06520-8063

    United States

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Ratner's laboratory is working on new targeted drugs for ovarian cancer in order to provide patients with truly personalized care. Her work additionally focuses on reversing chemotherapy resistance in ovarian and uterine cancers.

Extensive Research Description

Dr. Ratner's laboratory is working on new targeted drugs for ovarian cancer in order to provide patients with truly personalized care. Her work additionally focuses on reversing chemotherapy resistance in ovarian and uterine cancers.

Clinical Trials

ConditionsStudy Title
Corpus UteriA Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer
Corpus UteriA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
Corpus Uteri; Other Female GenitalA Phase II Evaluation of Afatinib
CervixA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
OvaryA Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Trial of Exercise and Lifestyle (TEAL) Intervention
Corpus UteriA Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Edit Profile